Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-752-6170
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees61
OptionableOptionable
Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions
What is Cidara Therapeutics' stock symbol?
Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."
How were Cidara Therapeutics' earnings last quarter?
Cidara Therapeutics Inc (NASDAQ:CDTX) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.60) by $0.11. View Cidara Therapeutics' Earnings History.
When is Cidara Therapeutics' next earnings date?
What price target have analysts set for CDTX?
4 equities research analysts have issued twelve-month price objectives for Cidara Therapeutics' stock. Their predictions range from $8.00 to $15.00. On average, they expect Cidara Therapeutics' stock price to reach $12.3333 in the next year. This suggests a possible upside of 318.1% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics.
What is the consensus analysts' recommendation for Cidara Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics.
What are Wall Street analysts saying about Cidara Therapeutics stock?
Here are some recent quotes from research analysts about Cidara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (1/16/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we reiterate our OW rating and 12-month PT of $15. We think the Street underappreciates the sales potential of CDTX’s two pipeline assets: 1) Rezafungin for the treatment of life-threatening invasive fungal infections, and 2) Cloudbreak, an antimicrobial immunotherapy for the treatment of MDR gram-negative bacterial infections. Therefore, we expect pipeline advancements to drive upward earnings revisions to levels not yet reflected in consensus expectations. This should move CDTX’s stock higher." (8/8/2018)
Has Cidara Therapeutics been receiving favorable news coverage?
Press coverage about CDTX stock has been trending very positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cidara Therapeutics earned a news impact score of 3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Are investors shorting Cidara Therapeutics?
Cidara Therapeutics saw a drop in short interest in December. As of December 14th, there was short interest totalling 472,790 shares, a drop of 64.2% from the November 30th total of 1,322,026 shares. Based on an average trading volume of 135,263 shares, the days-to-cover ratio is currently 3.5 days. Currently, 2.4% of the shares of the stock are short sold. View Cidara Therapeutics' Current Options Chain.
Who are some of Cidara Therapeutics' key competitors?
Some companies that are related to Cidara Therapeutics include Avrobio (AVRO), MeiraGTx (MGTX), Voyager Therapeutics (VYGR), Eiger Biopharmaceuticals (EIGR), Gamida Cell (GMDA), Translate Bio (TBIO), Sutro Biopharma (STRO), Adverum Biotechnologies (ADVM), Allena Pharmaceuticals (ALNA), LogicBio Therapeutics (LOGC), La Jolla Pharmaceutical (LJPC), Compugen (CGEN), ADMA Biologics (ADMA), Erytech Pharma (ERYP) and Fennec Pharmaceuticals (FENC).
Who are Cidara Therapeutics' key executives?
Cidara Therapeutics' management team includes the folowing people:
- Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 63)
- Dr. Taylor Sandison, Chief Medical Officer (Age 46)
- Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 41)
- Mr. James E. Levine, Chief Financial Officer (Age 47)
- Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 49)
When did Cidara Therapeutics IPO?
(CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.
How do I buy shares of Cidara Therapeutics?
Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cidara Therapeutics' stock price today?
One share of CDTX stock can currently be purchased for approximately $2.95.
How big of a company is Cidara Therapeutics?
Cidara Therapeutics has a market capitalization of $81.87 million. The biotechnology company earns $-55,720,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. Cidara Therapeutics employs 61 workers across the globe.
What is Cidara Therapeutics' official website?
How can I contact Cidara Therapeutics?
Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]
MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
